Human monoclonal antibodies against IP-10 (MDX-1100/BMS-936557 and NI-0801) have been well tolerated in clinical trials to treat several inflammatory conditions, such as rheumatoid arthritis, cirrhosis, and inflammatory bowel disorder. Here, CXCL10 is linked to rheumatoid arthritis.